DLin-MC3-DMA is an ionizable lipid used in combination with other lipids for encapsulation of RNA and DNA into lipid nanoparticles (LNPs). Administration of DLin-MC3-DMA based LNPs have delivered siRNA and reduced Factor VII levels in mice. Delivery of BCR-ABL siRNA reduced leukemic burden in a mouse model of chronic myeloid leukemia (CML).
This product is for research use only and not for human use. Additional information can be found here.
References
1) Jayaraman, M., Ansell, S.M., Mui, B.L., et al. (2012) “Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.” Angew. Chem. Int. Ed. Engl. 51(34), 8529-8533. DOI: 10.1002/anie. 201203263.
2) Kulkarni, JA, Myhre, JL, Chen, S, et al. (2017) “Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA.” Nanomedicine. 13(4):1377-1387. DOI: 10.1016/j.nano.2016.12.014.
3) Jyotsana N, Sharma A, Chaturvedi A, et al. (2019) “Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.” Ann Hematol. 98(8):1905-1918. doi: 10.1007/s00277-019-03713-y.
